AN2 Therapeutics, Inc. financial data

Symbol
ANTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1800 El Camino Real, Suite D, Menlo Park, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 875 % -58.8%
Debt-to-equity 10.7 % +3.2%
Return On Equity -57.6 % +2.32%
Return On Assets -52.1 % +2.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 29.9M shares +0.46%
Common Stock, Shares, Outstanding 29.9M shares +0.43%
Entity Public Float 109M USD -8.6%
Weighted Average Number of Shares Outstanding, Basic 29.8M shares +16.4%
Weighted Average Number of Shares Outstanding, Diluted 29.8M shares +16.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 50M USD +2.68%
General and Administrative Expense 14.8M USD +1.1%
Operating Income (Loss) -67M USD -5.86%
Net Income (Loss) Attributable to Parent -60.7M USD -1.71%
Earnings Per Share, Basic -1.96 USD/shares -109%
Earnings Per Share, Diluted -1.96 USD/shares -109%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.5M USD +2.72%
Cash, Cash Equivalents, and Short-term Investments 95.3M USD -16%
Assets, Current 97.7M USD -22.7%
Other Assets, Noncurrent 1.04M USD +44.9%
Assets 97.7M USD -36.5%
Accounts Payable, Current 1.71M USD -64.9%
Employee-related Liabilities, Current 2.11M USD -3.92%
Accrued Liabilities, Current 4.92M USD -27.5%
Liabilities, Current 10M USD -32.5%
Liabilities 10M USD -32.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 112K USD
Retained Earnings (Accumulated Deficit) -198M USD -44.1%
Stockholders' Equity Attributable to Parent 87.7M USD -36.9%
Liabilities and Equity 97.7M USD -36.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.6M USD -51.7%
Net Cash Provided by (Used in) Financing Activities 349K USD +75.4%
Net Cash Provided by (Used in) Investing Activities 26.3M USD +141%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 29.9M shares +0.43%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.05M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.5M USD +2.72%
Deferred Tax Assets, Valuation Allowance 41.8M USD +92.1%
Cash and Cash Equivalents, Period Increase (Decrease) 70.4M USD -9.95%
Deferred Tax Assets, Gross 41.8M USD +92.1%
Operating Lease, Liability 53K USD +6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60.5M USD -2.04%
Lessee, Operating Lease, Liability, to be Paid 54K USD
Operating Lease, Liability, Current 13K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year One 54K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD
Deferred Tax Assets, Operating Loss Carryforwards 20.8M USD +51.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.46M USD +86.6%
Operating Lease, Payments 80K USD
Additional Paid in Capital 286M USD +3.31%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.86M USD +16.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%